The Many Effects of Complement C3- and C5-Binding Proteins in Renal Injury

Seminars in Nephrology

Volumn 27, Issue 3, 2007, Pages 321-337

  Puri, Tipu S ^a   Quigg, Richard J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

2 integrins; Complement; innate immunity; regulators of complement activation

Indexed keywords

BETA1 INTEGRIN; BETA2 INTEGRIN; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR H; GUANINE NUCLEOTIDE BINDING PROTEIN; LIGANDIN;

ARTICLE; COMPLEMENT ACTIVATION; DENDRITIC CELL; HUMAN; KIDNEY INJURY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; COMPLEMENT C3; COMPLEMENT C5; HUMANS; KIDNEY DISEASES;

EID: 34249104864     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2007.02.005     Document Type: Article

References (212)

1. Walport M.J. Advances in immunology: complement (first of two parts). N Engl J Med 344 (2001) 1058-1066
2. Liszewski M.K., and Atkinson J.P. The complement system. In: Paul W.E. (Ed). Fundamental immunology (1993), Raven Press, New York 917-939
3. Holers V.M. Complement. In: Rich R. (Ed). Principles and practices of clinical immunology (2001), Mosby, St. Louis 211-218
4. Tang S., Zhou W., Sheerin N.S., et al. Contribution of renal secreted complement C3 to the circulating pool in humans. J Immunol 162 (1999) 4336-4341
5. Zhou W., Marsh J.E., and Sacks S.H. Intrarenal synthesis of complement. Kidney Int 59 (2001) 1227-1235
6. Niculescu F., and Rus H. Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells. Immunol Res 24 (2001) 191-199
7. Bohana-Kashtan O., Ziporen L., Donin N., et al. Cell signals transduced by complement. Mol Immunol 41 (2004) 583-597
8. Cybulsky A.V., Quigg R.J., and Salant D.J. Experimental membranous nephropathy redux. Am J Physiol 289 (2005) F660-F671
9. Wetsel R.A. Structure, function and cellular expression of complement anaphylatoxin receptors. Curr Opin Immunol 7 (1995) 48-53
10. Gerard C., and Gerard N.P. C5a anaphylatoxin and its seven transmembrane-segment receptor. Annu Rev Immunol 12 (1994) 775-808
11. Guo R.F., and Ward P.A. Role of C5a in inflammatory responses. Annu Rev Immunol 23 (2005) 821-852
12. Klco J.M., Wiegand C.B., Narzinski K., et al. Essential role for the second extracellular loop in C5a receptor activation. Nat Struct Mol Biol 12 (2005) 320-326
13. Klco J.M., Nikiforovich G.V., and Baranski T.J. Genetic analysis of the first and third extracellular loops of the C5a receptor reveals an essential WXFG motif in the first loop. J Biol Chem 281 (2006) 12010-12019
14. Matthews K.W., Mueller-Ortiz S.L., and Wetsel R.A. Carboxypeptidase N: a pleiotropic regulator of inflammation. Mol Immunol 40 (2004) 785-793
15. Drouin S.M., Kildsgaard J., Haviland J., et al. Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J Immunol 166 (2001) 2025-2032
16. Laudes I.J., Chu J.C., Huber-Lang M., et al. Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol 169 (2002) 5962-5970
17. Hunt J.R., Martin C.B., and Martin B.K. Transcriptional regulation of the murine C5a receptor gene: NF-Y is required for basal and LPS induced expression in macrophages and endothelial cells. Mol Immunol 42 (2005) 1405-1415
18. Martin C.B., and Martin B.K. Characterization of the murine C3a receptor enhancer-promoter: expression control by an activator protein 1 sequence and an Ets-like site. J Immunol 175 (2005) 3123-3132
19. Haviland D.L., McCoy R.L., Whitehead W.T., et al. Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung. J Immunol 154 (1995) 1861-1869
20. Shushakova N., Tkachuk N., Dangers M., et al. Urokinase-induced activation of the gp130/Tyk2/Stat3 pathway mediates a pro-inflammatory effect in human mesangial cells via expression of the anaphylatoxin C5a receptor. J Cell Sci 118 (2005) 2743-2753
21. Monk P.N., Pease J.E., and Barker M.D. C5a stimulus-secretion coupling in rat basophilic leukaemia (RBL-2H3) cells transfected with the human C5a receptor is mediated by pertussis and cholera toxin-sensitive G proteins. Biochem Mol Biol Int 32 (1994) 13-20
22. Lo R.K., Cheung H., and Wong Y.H. Constitutively active Galpha16 stimulates STAT3 via a c-Src/JAK- and ERK-dependent mechanism. J Biol Chem 278 (2003) 52154-52165
23. Yang M., Sang H., Rahman A., et al. G alpha 16 couples chemoattractant receptors to NF-kappa B activation. J Immunol 166 (2001) 6885-6892
24. Perianayagam M.C., Balakrishnan V.S., Pereira B.J., et al. C5a delays apoptosis of human neutrophils via an extracellular signal-regulated kinase and Bad-mediated signalling pathway. Eur J Clin Invest 34 (2004) 50-56
25. Albrecht E.A., Chinnaiyan A.M., Varambally S., et al. C5a-induced gene expression in human umbilical vein endothelial cells. Am J Pathol 164 (2004) 849-859
26. Braun M.C., Reins R.Y., Li T.B., et al. Renal expression of the C3a receptor and functional responses of primary human proximal tubular epithelial cells. J Immunol 173 (2004) 4190-4196
27. Venkatesha R.T., Berla T.E., Zaidi A.K., et al. Distinct regulation of C3a-induced MCP-1/CCL2 and RANTES/CCL5 production in human mast cells by extracellular signal regulated kinase and PI3 kinase. Mol Immunol 42 (2005) 581-587
28. Guo R.F., Riedemann N.C., Sun L., et al. Divergent signaling pathways in phagocytic cells during sepsis. J Immunol 177 (2006) 1306-1313
29. Grant E.P., Picarella D., Burwell T., et al. Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis. J Exp Med 196 (2002) 1461-1471
30. Ahamed J., Venkatesha R.T., Thangam E.B., et al. C3a enhances nerve growth factor-induced NFAT activation and chemokine production in a human mast cell line, HMC-1. J Immunol 172 (2004) 6961-6968
31. Werfel T., Kirchhoff K., Wittmann M., et al. Activated human T lymphocytes express a functional C3a receptor. J Immunol 165 (2000) 6599-6605
32. Gutzmer R., Lisewski M., Zwirner J., et al. Human monocyte-derived dendritic cells are chemoattracted to C3a after up-regulation of the C3a receptor with interferons. Immunology 111 (2004) 435-443
33. Hawlisch H., Wills-Karp M., Karp C.L., et al. The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol Immunol 41 (2004) 123-131
34. Nataf S., Davoust N., Ames R.S., et al. Human T cells express the C5a receptor and are chemoattracted to C5a. J Immunol 162 (1999) 4018-4023
35. Tsuji R.F., Kawikova I., Ramabhadran R., et al. Early local generation of C5a initiates the elicitation of contact sensitivity by leading to early T cell recruitment. J Immunol 165 (2000) 1588-1598
36. Bao L., Osawe I., Haas M., et al. Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis. J Immunol 175 (2005) 1602-1610
37. Wilmer W.A., Kaumaya P.T., Ember J.A., et al. Receptors for the anaphylatoxin C5a (CD88) on human mesangial cells. J Immunol 160 (1998) 5646-5652
38. Braun M., and Davis III A.E. Cultured human glomerular mesangial cells express the C5a receptor. Kidney Int 54 (1998) 1542-1549
39. Zahedi R., Braun M., Wetsel R.A., et al. The C5a receptor is expressed by human renal proximal tubular epithelial cells. Clin Exp Immunol 121 (2000) 226-233
40. Fayyazi A., Scheel O., Werfel T., et al. The C5a receptor is expressed in normal renal proximal tubular but not in normal pulmonary or hepatic epithelial cells. Immunology 99 (2000) 38-45
41. Bao L., Osawe I., Puri T., et al. C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol 35 (2005) 3012-3020
42. Wilson C.B. Renal response to immunologic glomerular injury. In: Brenner B.M. (Ed). The kidney (1996), WB Saunders, Philadelphia 1253-1391
43. Kildsgaard J., Hollmann T.J., Matthews K.W., et al. Targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. J Immunol 165 (2000) 5406-5409
44. Humbles A.A., Lu B., Nilsson C.A., et al. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 406 (2000) 998-1001
45. Hopken U.E., Lu B., Gerard N.P., et al. Impaired inflammatory responses in the reverse arthus reaction through genetic deletion of the C5a receptor. J Exp Med 186 (1997) 749-756
46. Bozic C.R., Lu B., Hopken U.E., et al. Neurogenic amplification of immune complex inflammation. Science 273 (1996) 1722-1725
47. Pickering M.C., Warren J., Rose K.L., et al. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci U S A 103 (2006) 9649-9654
48. Trendelenburg M., Fossati-Jimack L., Cortes-Hernandez J., et al. The role of complement in cryoglobulin-induced immune complex glomerulonephritis. J Immunol 175 (2005) 6909-6914
49. Wenderfer S.E., Ke B., Hollmann T.J., et al. C5a receptor deficiency attenuates T cell function and renal disease in MRLlpr mice. J Am Soc Nephrol 16 (2005) 3572-3582
50. Kondo C., Mizuno M., Nishikawa K., et al. The role of C5a in the development of thrombotic glomerulonephritis in rats. Clin Exp Immunol 124 (2001) 323-329
51. Salmon J.E., and Girardi G. The role of complement in the antiphospholipid syndrome. Curr Dir Autoimmun 7 (2004) 133-148
52. Farkas I., Baranyi L., Liposits Z.S., et al. Complement C5a anaphylatoxin fragment causes apoptosis in TGW neuroblastoma cells. Neuroscience 86 (1998) 903-911
53. Welch T.R., Frenzke M., Witte D., et al. C5a is important in the tubulointerstitial component of experimental immune complex glomerulonephritis. Clin Exp Immunol 13 (2002) 43-48
54. Lambrecht B.N. An unexpected role for the anaphylatoxin C5a receptor in allergic sensitization. J Clin Invest 116 (2006) 628-632
55. Kohl J., and Wills-Karp M. Complement regulates inhalation tolerance at the dendritic cell/T cell interface. Mol Immunol 44 (2007) 44-56
56. Hawlisch H., and Kohl J. Complement and Toll-like receptors: key regulators of adaptive immune responses. Mol Immunol 43 (2006) 13-21
57. Riedemann N.C., Guo R.F., Laudes I.J., et al. C5a receptor and thymocyte apoptosis in sepsis. FASEB J 16 (2002) 887-888
58. Ward P.A. The dark side of C5a in sepsis. Nat Rev Immunol 4 (2004) 133-142
59. Shushakova N., Skokowa J., Schulman J., et al. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcγRs in immune complex-induced lung disease. J Clin Invest 110 (2002) 1823-1830
60. Kumar V., Ali S.R., Konrad S., et al. Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J Clin Invest 116 (2006) 512-520
61. Konrad S., Baumann U., Schmidt R.E., et al. Intravenous immunoglobulin (IVIG)-mediated neutralisation of C5a: a direct mechanism of IVIG in the maintenance of a high Fc gammaRIIB to Fc gammaRIII expression ratio on macrophages. Br J Haematol 134 (2006) 345-347
62. Ward P.A., and Hill J.H. C5 chemotactic fragments produced by an enzyme in lysosomal granules of neutrophils. J Immunol 104 (1970) 535-543
63. Huber-Lang M., Sarma J.V., Zetoune F.S., et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 12 (2006) 682-687
64. Hawlisch H., Belkaid Y., Baelder R., et al. C5a negatively regulates toll-like receptor 4-induced immune responses. Immunity 22 (2005) 415-426
65. Barlow P.N., Baron M., Norman D.G., et al. Secondary structure of a complement control protein module by two-dimensional 1H NMR. Biochemistry 30 (1991) 997-1004
66. Barlow P.N., Norman D.G., Steinkasserer A., et al. Solution structure of the fifth repeat of factor H: a second example of the complement control protein module. Biochemistry 31 (1992) 3626-3634
67. Kristensen T., Wetsel R.A., and Tack B.F. Structural analysis of human complement protein H: homology with C4b binding protein, beta 2-glycoprotein I, and the Ba fragment of B2. J Immunol 136 (1986) 3407-3411
68. Kristensen T., and Tack B.F. Murine protein H is comprised of 20 repeating units, 61 amino acids in length. Proc Natl Acad Sci U S A 83 (1986) 3963-3967
69. Demberg T., Pollok-Kopp B., Gerke D., et al. Rat complement factor H: molecular cloning, sequencing and quantification with a newly established ELISA. Scand J Immunol 56 (2002) 149-160
70. Aslam M., and Perkins S.J. Folded-back solution structure of monomeric factor H of human complement by synchrotron X-ray and neutron scattering, analytical ultracentrifugation and constrained molecular modelling. J Mol Biol 309 (2001) 1117-1138
71. Oppermann M., Manuelian T., Jozsi M., et al. The C-terminus of complement regulator factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin Exp Immunol 144 (2006) 342-352
72. Pangburn M.K., Pangburn K.L., Koistinen V., et al. Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b, and target in the alternative pathway of human complement. J Immunol 164 (2000) 4742-4751
73. Sharma A.K., and Pangburn M.K. Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. Proc Natl Acad Sci U S A 93 (1996) 10996-11001
74. Sharma A.K., and Pangburn M.K. Localization by site-directed mutagenesis of the site in human complement factor H that binds to Streptococcus pyogenes M protein. Infect Immun 65 (1997) 484-487
75. Ram S., Sharma A.K., Simpson S.D., et al. A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J Exp Med 187 (1998) 743-752
76. Gordon D.L., Kaufman R.M., Blackmore T.K., et al. Identification of complement regulatory domains in human factor H. J Immunol 155 (1995) 348-356
77. Blackmore T.K., Hellwage J., Sadlon T.A., et al. Identification of the second heparin-binding domain in human complement factor H. J Immunol 160 (1998) 3342-3348
78. Blackmore T.K., Sadlon T.A., Ward H.M., et al. Identification of a heparin binding domain in the seventh short consensus repeat of complement factor H. J Immunol 157 (1996) 5422-5427
79. Jokiranta T.S., Cheng Z.Z., Seeberger H., et al. Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. Am J Pathol 167 (2005) 1173-1181
80. Jozsi M., Heinen S., Hartmann A., et al. Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions. J Am Soc Nephrol 17 (2006) 170-177
81. Harrison R.A., and Lachmann P.J. The physiological breakdown of the third component of human complement. Mol Immunol 17 (1980) 9-20
82. Pickering M.C., Cook H.T., Warren J., et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 31 (2002) 424-428
83. Rodriguez de Cordoba S., Esparza-Gordillo J., Goicoechea de J.E., et al. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 41 (2004) 355-367
84. Ollert M.W., David K., Bredehorst R., et al. Classical complement pathway activation on nucleated cells. Role of factor H in the control of deposited C3b. J Immunol 155 (1995) 4955-4962
85. Schwaeble W., Zwirner J., Schulz T.F., et al. Human complement factor H: expression of an additional truncated gene product of 43 kDa in human liver. Eur J Immunol 17 (1987) 1485-1489
86. Saland J.M., Emre S.H., Shneider B.L., et al. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant 6 (2006) 1948-1952
87. Vaziri-Sani F., Holmberg L., Sjoholm A.G., et al. Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome. Kidney Int 69 (2006) 981-988
88. Alexander J.J., Aneziokoro O.G.B., Chang A., et al. Distinct and separable roles of the complement system in factor H-deficient bone marrow chimeric mice with immune complex disease. J Am Soc Nephrol 17 (2006) 1354-1361
89. Gerritsma J.S., Gerritsen A.F., De Ley M., et al. Interferon-gamma induces biosynthesis of complement components C2, C4 and factor H by human proximal tubular epithelial cells. Cytokine 9 (1997) 276-283
90. Timmerman J.J., Beersma M.F., Gijlswijk-Janssen D.J., et al. Differential effects of cytomegalovirus infection on complement synthesis by human mesangial cells. Clin Exp Immunol 109 (1997) 518-525
91. Song D., Zhou W., Sheerin S.H., et al. Compartmental localization of complement component transcripts in the normal human kidney. Nephron 78 (1998) 15-22
92. Noris M., and Remuzzi G. Complement factor h gene abnormalities in haemolytic uraemic syndrome: from point mutations to hybrid gene. PLoS Med 3 (2006) e432
93. Alexander J.J., Wang Y., Chang A., et al. Mouse podocyte complement factor H: the functional analogue to human complement receptor 1. J Am Soc Nephrol 18 (2007) 1157-1166
94. Alexander J.J., Hack B.K., Cunningham P.N., et al. A protein with characteristics of factor H is present on rodent platelets and functions as the immune adherence receptor. J Biol Chem 276 (2001) 32129-32135
95. Ren G., Doshi M., Hack B.K., et al. Rat glomerular epithelial cells produce and bear factor H on their surface which is upregulated under complement attack. Kidney Int 64 (2003) 914-922
96. Pangburn M.K. Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement. Immunopharmacology 49 (2000) 149-157
97. Richards A., Buddles M.R., Donne R.L., et al. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet 68 (2001) 485-490
98. Manuelian T., Hellwage J., Meri S., et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 111 (2003) 1181-1190
99. Saunders R.E., and Perkins S.J. A user's guide to the interactive Web database of factor H-associated hemolytic uremic syndrome. Semin Thromb Hemost 32 (2006) 160-168
100. Zipfel P.F., Heinen S., Jozsi M., et al. Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol 43 (2006) 97-106
101. Zipfel P.F., Misselwitz J., Licht C., et al. The role of defective complement control in hemolytic uremic syndrome. Semin Thromb Hemost 32 (2006) 146-154
102. Sanchez-Corral P., Perez-Caballero D., Huarte O., et al. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am J Hum Genet 71 (2002) 1285-1295
103. Bonnardeaux A., and Pichette V. Complement dysregulation in haemolytic uraemic syndrome. Lancet 362 (2003) 1514-1515
104. Noris M., and Remuzzi G. Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management?. Nat Clin Pract Nephrol 1 (2005) 2-3
105. Dragon-Durey M.A., and Fremeaux-Bacchi V. Atypical haemolytic uraemic syndrome and mutations in complement regulator genes. Springer Semin Immunopathol 27 (2005) 359-374
106. Dragon-Durey M.A., Loirat C., Cloarec S., et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 16 (2005) 555-563
107. Kavanagh D., Kemp E.J., Mayland E., et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 16 (2005) 2150-2155
108. Noris M., Brioschi S., Caprioli J., et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 362 (2003) 1542-1547
109. Warwicker P., Donne R.L., Goodship J.A., et al. Familial relapsing haemolytic uraemic syndrome and complement factor H deficiency. Nephrol Dial Transplant 14 (1999) 1229-1233
110. Saunders R.E., Abarrategui-Garrido C., Fremeaux-Bacchi V., et al. The interactive factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Hum Mutat 28 (2007) 222-234
111. Alexander J.J., Pickering M.C., Haas M., et al. Complement factor H limits immune complex deposition and prevents inflammation and scarring in glomeruli of mice with chronic serum sickness. J Am Soc Nephrol 16 (2005) 52-57
112. Paul M.S., Aegerter M., O'Brien S.E., et al. The murine complement receptor gene family. I. Analysis of mCRY gene products and their homology to human CR1. J Immunol 142 (1989) 582-589
113. Molina H., Wong W., Kinoshita T., et al. Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1. J Exp Med 175 (1992) 121-129
114. Quigg R.J., Lo C.F., Alexander J.J., et al. Molecular characterization of rat Crry: widespread distribution of two alternative forms of Crry mRNA. Immunogenetics 42 (1995) 362-367
115. Harris C.L., Rushmere N.K., and Morgan B.P. Molecular and functional analysis of mouse decay accelerating factor (CD55). Biochem J 341 (1999) 821-829
116. Kim Y.-U., Kinoshita T., Molina H., et al. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J Exp Med 181 (1995) 151-159
117. Manchester M., Liszewski M.K., Atkinson J.P., et al. Multiple isoforms of CD46 (membrane cofactor protein) serve as receptors for measles virus. Proc Natl Acad Sci U S A 91 (1994) 2161-2165
118. O'Brien D.P., Israel D.A., Krishna U., et al. The role of decay-accelerating factor as a receptor for Helicobacter pylori and a mediator of gastric inflammation. J Biol Chem 281 (2006) 13317-13323
119. Liszewski M.K., Kemper C., Price J.D., et al. Emerging roles and new functions of CD46. Springer Semin Immunopathol 27 (2005) 345-358
120. Lea S. Interactions of CD55 with non-complement ligands. Biochem Soc Trans 30 (2002) 1014-1019
121. Davis L.S., Patel S.S., Atkinson J.P., et al. Decay-accelerating factor functions as a signal transducing molecule for human T cells. J Immunol 141 (1988) 2246-2252
122. fyn 1. J Immunol 149 (1992) 3535-3541
123. Liu J., Miwa T., Hilliard B., et al. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med 201 (2005) 567-577
124. Hamann J., Vogel B., van Schijndel G.M., et al. The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med 184 (1996) 1185-1189
125. Qian Y.M., Haino M., Kelly K., et al. Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55). Immunology 98 (1999) 303-311
126. Heeger P.S., Lalli P.N., Lin F., et al. Decay-accelerating factor modulates induction of T cell immunity. J Exp Med 201 (2005) 1523-1530
127. Atkinson J.P. C5a and Fcgamma receptors: a mutual admiration society. J Clin Invest 116 (2006) 304-306
128. Capasso M., Durrant L.G., Stacey M., et al. Costimulation via CD55 on human CD4+ T cells mediated by CD97. J Immunol 177 (2006) 1070-1077
129. Marie J.C., Astier A.L., Rivailler P., et al. Linking innate and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell induced inflammation. Nat Immunol 3 (2002) 659-666
130. Zaffran Y., Destaing O., Roux A., et al. CD46/CD3 costimulation induces morphological changes of human T cells and activation of Vav, Rac, and extracellular signal-regulated kinase mitogen-activated protein kinase. J Immunol 167 (2001) 6780-6785
131. Astier A., Trescol-Biemont M.C., Azocar O., et al. Cutting edge: CD46, a new costimulatory molecule for T cells, that induces p120CBL and LAT phosphorylation. J Immunol 164 (2000) 6091-6095
132. Kemper C., Chan A.C., Green J.M., et al. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 421 (2003) 388-392
133. Meiffren G., Flacher M., Azocar O., et al. Cutting edge: abortive proliferation of CD46-induced Tr1-like cells due to a defective Akt/Survivin signaling pathway. J Immunol 177 (2006) 4957-4961
134. Astier A.L., Meiffren G., Freeman S., et al. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest 116 (2006) 3252-3257
135. Ludford-Menting M.J., Thomas S.J., Crimeen B., et al. A functional interaction between CD46 and DLG4: a role for DLG4 in epithelial polarization. J Biol Chem 277 (2002) 4477-4484
136. Crimeen-Irwin B., Ellis S., Christiansen D., et al. Ligand binding determines whether CD46 is internalized by clathrin-coated pits or macropinocytosis. J Biol Chem 278 (2003) 46927-46937
137. Ludford-Menting M.J., Oliaro J., Sacirbegovic F., et al. A network of PDZ-containing proteins regulates T cell polarity and morphology during migration and immunological synapse formation. Immunity 22 (2005) 737-748
138. Oliaro J., Pasam A., Waterhouse N.J., et al. Ligation of the cell surface receptor, CD46, alters T cell polarity and response to antigen presentation. Proc Natl Acad Sci U S A 103 (2006) 18685-18690
139. Li B., Sallee C., Dehoff M., et al. Mouse Crry/p65: characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF. J Immunol 151 (1993) 4295-4305
140. Fernandez-Centeno E., de O.G., Rojo J.M., et al. Crry/p65, a membrane complement regulatory protein, has costimulatory properties on mouse T cells. J Immunol 164 (2000) 4533-4542
141. Rsenovic-Ranin N., Vucevic D., Okada N., et al. A monoclonal antibody to the rat Crry/p65 antigen, a complement regulatory membrane protein, stimulates adhesion and proliferation of thymocytes. Immunology 100 (2000) 334-344
142. Antic S.J., Vucevic D., Majstorovic I., et al. The role of rat Crry, a complement regulatory protein, in proliferation of thymocytes. Life Sci 75 (2004) 3053-3062
143. Jimenez-Perianez A., Ojeda G., Criado G., et al. Complement regulatory protein Crry/p65-mediated signaling in T lymphocytes: role of its cytoplasmic domain and partitioning into lipid rafts. J Leukoc Biol 78 (2005) 1386-1396
144. Endoh M., Yamashina M., Ohi H., et al. Immunohistochemical demonstration of membrane cofactor protein (MCP) of complement in normal and diseased kidney tissues. Clin Exp Immunol 94 (1993) 182-188
145. Ichida S., Yuzawa Y., Okada H., et al. Localization of the complement regulatory proteins in the normal human kidney. Kidney Int 46 (1994) 89-96
146. Cosio F.G., Sedmak D.D., Mahan J.D., et al. Localization of decay accelerating factor in normal and diseased kidneys. Kidney Int 36 (1989) 100-107
147. Quigg R.J., Nicholson-Weller A., Cybulsky A.V., et al. Decay accelerating factor regulates complement activation on glomerular epithelial cells. J Immunol 142 (1989) 877-882
148. Lin F., Fukuoka Y., Spicer A., et al. Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies. Immunology 104 (2001) 215-225
149. Bao L., Spiller O.B., St J.P., et al. Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes. Kidney Int 62 (2002) 2010-2021
150. Inoue N., Ikawa M., Nakanishi T., et al. Disruption of mouse CD46 causes an accelerated spontaneous acrosome reaction in sperm. Mol Cell Biol 23 (2003) 2614-2622
151. Lin F., Salant D.J., Meyerson H., et al. Respective roles of decay-accelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic serum nephritis. J Immunol 172 (2004) 2636-2642
152. Lin F., Emancipator S.N., Salant D.J., et al. Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis. Lab Invest 82 (2002) 563-569
153. Sogabe H., Nangaku M., Ishibashi Y., et al. Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. J Immunol 167 (2001) 2791-2797
154. Miwa T., Maldonado M.A., Zhou L., et al. Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice. Am J Pathol 161 (2002) 1077-1086
155. Cosio F.G., Shibata T., Rovin B.H., et al. Effects of complement activation products on the synthesis of decay accelerating factor and membrane cofactor protein by human mesangial cells. Kidney Int 46 (1994) 986-992
156. Thomas D.J., and Lublin D.M. Identification of 5'-flanking regions affecting the expression of the human decay accelerating factor gene and their role in tissue-specific expression. J Immunol 150 (1993) 151-160
157. Moutabarrik A., Nakanishi I., Namiki M., et al. Cytokine-mediated regulation of the surface expression of complement regulatory proteins, CD46(MCP), CD55(DAF), and CD59 on human vascular endothelial cells. Lymphokine Cytokine Res 12 (1993) 167-172
158. Song W.C., Deng C., Raszmann K., et al. Mouse decay-accelerating factor: selective and tissue-specific induction by estrogen of the gene encoding the glycosylphosphatidylinositol-anchored form. J Immunol 157 (1996) 4166-4172
159. Spiller O.B., Criado-Garcia O., Rodriguez D.C., et al. Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin Exp Immunol 121 (2000) 234-241
160. Cauvi D.M., Cauvi G., and Pollard K.M. Constitutive expression of murine decay-accelerating factor 1 is controlled by the transcription factor Sp1. J Immunol 177 (2006) 3837-3847
161. Quigg R.J., Holers V.M., Morgan B.P., et al. Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis. J Immunol 154 (1995) 3437-3443
162. Quigg R.J., Morgan B.P., Holers V.M., et al. Complement regulation in the rat glomerulus: Crry and CD59 regulate complement in glomerular mesangial and endothelial cells. Kidney Int 48 (1995) 412-421
163. Thurman J.M., Ljubanovic D., Royer P.A., et al. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest 116 (2006) 357-368
164. Xu C., Mao D., Holers V.M., et al. A critical role for murine complement regulator Crry in fetomaternal tolerance. Science 287 (2000) 498-501
165. Nishikage H., Baranyi L., Okada H., et al. Role of a complement regulatory protein in rat mesangial glomerulonephritis. J Am Soc Nephrol 6 (1995) 234-242
166. Schiller B., He C., Salant D.J., et al. Inhibition of complement regulation is key to the pathogenesis of Heymann nephritis. J Exp Med 188 (1998) 1353-1358
167. Nomura A., Nishikawa K., Yuzawa Y., et al. Tubulointerstitial injury induced in rats by a monoclonal antibody which inhibits function of a membrane inhibitor of complement. J Clin Invest 96 (1995) 2348-2356
168. Thurman J.M., Ljubanovic D., Edelstein C.L., et al. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol 170 (2003) 1517-1523
169. Thurman J.M., Royer P.A., Ljubanovic D., et al. Treatment with an inhibitory monoclonal antibody to mouse factor B protects mice from induction of apoptosis and renal ischemia/reperfusion injury. J Am Soc Nephrol 17 (2006) 707-715
170. Thurman J.M., Lucia M.S., Ljubanovic D., et al. Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney Int 67 (2005) 524-530
171. Bao L., Wang Y., Chang A., et al. Unrestricted C3 activation occurs in Crry-deficient kidneys and rapidly leads to chronic renal failure. J Am Soc Nephrol 18 (2007) 811-822
172. Krych-Goldberg M., and Atkinson J.P. Structure-function relationships of complement receptor type 1. Immunol Rev 180 (2001) 112-122
173. Gilbert H.E., Asokan R., Holers V.M., et al. The 15 SCR flexible extracellular domains of human complement receptor type 2 can mediate multiple ligand and antigen interactions. J Mol Biol 362 (2006) 1132-1147
174. Molina H., Kinoshita T., Inoue K., et al. A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2. J Immunol 145 (1990) 2974-2983
175. Klickstein L.B., Wong W.W., Smith J.A., et al. Human C3b/C4b receptor (CR1): demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristic of C3/C4 binding proteins. J Exp Med 165 (1987) 1095-1112
176. Gupta V., Gylling A., Alonso J.L., et al. The β-tail domain regulates physiologic ligand binding to integrin CD11b/CD18. Blood. Epub (2006) Dec 14.
177. Nishida N., Xie C., Shimaoka M., et al. Activation of leukocyte beta2 integrins by conversion from bent to extended conformations. Immunity 25 (2006) 583-594
178. Asokan R., Hua J., Young K.A., et al. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus. J Immunol 177 (2006) 383-394
179. Carel J.C., Myones B.L., Frazier B., et al. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection. J Biol Chem 265 (1990) 12293-12299
180. Cherukuri A., Shoham T., Sohn H.W., et al. The tetraspanin CD81 is necessary for partitioning of coligated CD19/CD21-B cell antigen receptor complexes into signaling-active lipid rafts. J Immunol 172 (2004) 370-380
181. Fearon D.T., and Carter R.H. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Ann Rev Immunol 13 (1995) 127-149
182. Holers V.M., and Kulik L. Complement receptor 2, natural antibodies and innate immunity: inter-relationships in B cell selection and activation. Mol Immunol 44 (2007) 64-72
183. Tedder T.F., Zhou L.J., and Engel P. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol Today 15 (1994) 437-442
184. Rossbacher J., Haberman A.M., Neschen S., et al. Antibody-independent B cell-intrinsic and -extrinsic roles for CD21/35. Eur J Immunol 36 (2006) 2384-2393
185. Barrington R.A., Zhang M., Zhong X., et al. CD21/CD19 coreceptor signaling promotes B cell survival during primary immune responses. J Immunol 175 (2005) 2859-2867
186. Gelfand M.C., Frank M.M., and Green I. A receptor for the third component of complement in the human renal glomerulus. J Exp Med 142 (1975) 1029-1034
187. Petterson E.E., Bhan A.K., Schneeberger E.E., et al. Glomerular C3 receptors in human renal disease. Kidney Int 13 (1978) 245-252
188. Moll S., Miot S., Sadallah S., et al. No complement receptor 1 stumps on podocytes in human glomerulopathies. Kidney Int 59 (2001) 160-168
189. Kinoshita T., Fujita T., and Tsunoda R. Expression of complement receptors CR1 and CR2 on murine follicular dendritic cells and B lymphocytes. In: Imai Y., Tew J.G., and Hoefsmit E.C.M. (Eds). Dendritic cells in lymphoid tissues (1991), Elsevier Science Publishers B.V, Amsterdam 271-276
190. Tan S.S., O'Toole E.M., Kurtz C.B., et al. Murine complement receptor gene expression: Cr2 gene transcripts are depressed during a high dose microbial challenge. Immunology 79 (1993) 82-88
191. Quigg R.J., Alexander J.J., Lo C.F., et al. Characterization of C3-binding proteins on mouse neutrophils and platelets. J Immunol 159 (1997) 2438-2444
192. Takahashi K., Kozono Y., Waldschmidt T.J., et al. Mouse complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21). Expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J Immunol 159 (1997) 1557-1569
193. Birmingham D.J., Hebert L.A., Cosio F.G., et al. Immune complex erythrocyte complement receptor interactions in vivo during induction of glomerulonephritis in nonhuman primates. J Lab Clin Med 116 (1990) 242-252
194. Kruger T., Benke D., Eitner F., et al. Identification and functional characterization of dendritic cells in the healthy murine kidney and in experimental glomerulonephritis. J Am Soc Nephrol 15 (2004) 613-621
195. Soos T.J., Sims T.N., Barisoni L., et al. CX3CR1+ interstitial dendritic cells form a contiguous network throughout the entire kidney. Kidney Int 70 (2006) 591-596
196. Wu X., Pippin J., and Lefkowith J.B. Attenuation of immune-mediated glomerulonephritis with an anti-CD11b monoclonal antibody. Am J Physiol 264 (1993) F715-F721
197. Tang T., Rosenkranz A., Assmann K.M., et al. A role for Mac-1 (CDIIb/CD18) in immune complex-stimulated neutrophil function in vivo: Mac-1 deficiency abrogates sustained Fcgamma receptor-dependent neutrophil adhesion and complement-dependent proteinuria in acute glomerulonephritis. J Exp Med 186 (1997) 1853-1863
198. Lefkowith J.B. Leukocyte migration in immune complex glomerulonephritis: role of adhesion receptors. Kidney Int 51 (1997) 1469-1475
199. Mulligan M.S., Johnson K.J., Todd III R.F., et al. Requirements for leukocyte adhesion molecules in nephrotoxic nephritis. J Clin Invest 91 (1993) 577-587
200. Krauss J.C., Poo H., Xue W., et al. Reconstitution of antibody-dependent phagocytosis in fibroblasts expressing Fc gamma receptor IIIB and the complement receptor type 3. J Immunol 153 (1994) 1769-1777
201. Suzuki Y., Shirato I., Okumura K., et al. Distinct contributions of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis. Kidney Int 54 (1998) 1166-1174
202. Kinoshita T., Takeda J., Hong K., et al. Monoclonal antibodies to mouse complement receptor type 1 (CR1). Their use in a distribution study showing that mouse erythrocytes and platelets are CR1-negative. J Immunol 140 (1988) 3066-3072
203. Fujigaki Y., Nagase M., and Honda N. Intraglomerular basement membrane translocation of immune complex (IC) in the development of passive in situ IC nephritis of rats. Am J Pathol 142 (1993) 831-842
204. Schreiner G.F., Kiely J.M., Cotran R.S., et al. Characterization of resident glomerular cells in the rat expressing Ia determinants and manifesting genetically restricted interactions with lymphocytes. J Clin Invest 68 (1981) 920-931
205. Wuthrich R.P., Glimcher L.H., Yui M.A., et al. MHC class II, antigen presentation and tumor necrosis factor in renal tubular epithelial cells. Kidney Int 37 (1990) 783-792
206. Yee J., and Neilson E.G. Immune modulation of biologic systems in renal somatic cells. Kidney Int 43 (1993) 128-134
207. Li S., Kurts C., Kontgen F., et al. Major histocompatibility complex class II expression by intrinsic renal cells is required for crescentic glomerulonephritis. J Exp Med 88 (1998) 597-602
208. Pratt J.R., Basheer S.A., and Sacks S.H. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 8 (2002) 582-587
209. Li K., Patel H., Farrar C.A., et al. Complement activation regulates the capacity of proximal tubular epithelial cell to stimulate alloreactive T cell response. J Am Soc Nephrol 15 (2004) 2414-2422
210. Pratt J.R., Harmer A.W., Levin J.L., et al. Influence of complement on the allospecific antibody response to a primary vascularized organ graft. Eur J Immunol 27 (1997) 2848-2853
211. Peng Q., Li K., Patel H., et al. Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype. J Immunol 176 (2006) 3330-3341
212. Brown K.M., Kondeatis E., Vaughan R.W., et al. Influence of donor C3 allotype on late renal-transplantation outcome. N Engl J Med 354 (2006) 2014-2023